相关实验视频
Updated: Jan 15, 2026

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.5K
洛拉提尼布在ALK阳性aNSCLC中的非典型安全概况:来自意大利专家小组的管理建议
Andrea Ardizzoni1, Diego Cortinovis2,3, Bruno Gori4
1Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Future oncology (London, England)
|January 14, 2026
概括
第一线洛拉提尼布为ALK阳性非小细胞肺癌提供了显著的长期益处. 这项研究详细介绍了洛拉提尼布.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 洛拉提尼布是一种第三代氨酸激酶抑制剂,用于ALK阳性高级非小细胞肺癌.
- 皇冠研究显示,一线洛拉提尼布改善了无进展生存率和内控制与5年内克里佐替尼布相比.
研究的目的:
- 分析洛拉提尼布的安全性,包括不良事件 (AE) 的发生率,严重程度,时间和管理.
- 概述洛拉提尼布相关毒性的安全管理框架.
- 在实践中为临床医生提供关于如何管理洛拉提尼布毒性的指导.
主要方法:
- 意大利专家小组的文献审查和临床专业知识.
- 从CROWN研究中分析AE数据.
- 开发洛拉提尼布的安全管理框架.
主要成果:
- 最常见的副作用是高胆固醇血症和高甘油三血症,它们出现得很早.
- 在CROWN研究中,大多数AE率在5年内保持稳定.
- 药理和非药理干预有效地管理了AE;剂量减少没有影响疗效.
结论:
- 洛拉提尼布的毒性通常是可预测和可管理的.
- 拟议的安全框架有助于AE预测,干预和缓解.
- 多学科合作和患者准备是优化洛拉提尼布治疗结果的关键.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
